Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting

BACKGROUND: Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial fibrillation (AF). Recently, rivaroxaban, a novel oral anticoagulant (NOAC) which offers some distinct advantages ov...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kleintjens, Joris, Li, Xiao, Simoens, Steven, Thijs, Vincent, Goethals, Marnix, Rietzschel, Ernst R., Asukai, Yumi, Saka, Ömer, Evers, Thomas, Faes, Petra, Vansieleghem, Stefaan, De Ruyck, Mimi
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2013
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3824571/
https://ncbi.nlm.nih.gov/pubmed/24030788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-013-0087-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars